Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Zimmer, Lisa [VerfasserIn]   i
 Utikal, Jochen [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
Titel:Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Verf.angabe:Lisa Zimmer, Simone M. Goldinger, Lars Hofmann, Carmen Loquai, Selma Ugurel, Ioannis Thomas, Maria I. Schmidgen, Ralf Gutzmer, Jochen S. Utikal, Daniela Göppner, Jessica C. Hassel, Friedegund Meier, Julia K. Tietze, Andrea Forschner, Carsten Weishaupt, Martin Leverkus, Renate Wahl, Ursula Dietrich, Claus Garbe, Michael C. Kirchberger, Thomas Eigentler, Carola Berking, Anja Gesierich, Angela M. Krackhardt, Dirk Schadendorf, Gerold Schuler, Reinhard Dummer, Lucie M. Heinzerling
E-Jahr:2016
Jahr:13 April 2016
Umfang:16 S.
Fussnoten:Gesehen am 02.07.2019
Titel Quelle:Enthalten in: European journal of cancer
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1992
Jahr Quelle:2016
Band/Heft Quelle:60(2016), Seite 210-225
ISSN Quelle:1879-0852
Abstract:Background - Anti-programmed cell death 1 (PD-1) antibodies represent an effective treatment option for metastatic melanoma and other cancer entities. They act via blockade of the PD-1 receptor, an inhibitor of the T-cell effector mechanisms that limit immune responses against tumours. As reported for ipilimumab, the anti-PD-1 antibodies pembrolizumab and nivolumab can induce immune-related adverse events (irAEs). These side-effects can involve skin, gastrointestinal tract, liver, the endocrine system and other organ systems. Since life-threatening and fatal irAEs have been reported, adequate diagnosis and management are essential. - Methods and findings - In total, 496 patients with metastatic melanoma from 15 skin cancer centres were treated with pembrolizumab or nivolumab. Two hundred forty two side-effects in 138 patients have been analysed. In 77 of the 138 patients side-effects affected the nervous system, respiratory tract, musculoskeletal system, heart, blood and eyes. Not yet reported side-effects such as meningo-(radiculitis), polyradiculitis, cardiac arrhythmia, asystolia, and paresis have been observed. Rare and difficult to manage side-effects such as myasthenia gravis are described in detail. - Conclusion - Anti-PD-1 antibodies can induce a plethora of irAEs. The knowledge of them will allow prompt diagnosis and improve the management resulting in decreased morbidity.
DOI:doi:10.1016/j.ejca.2016.02.024
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1016/j.ejca.2016.02.024
 Volltext: http://www.sciencedirect.com/science/article/pii/S0959804916001507
 DOI: https://doi.org/10.1016/j.ejca.2016.02.024
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Adverse event
 Anti-PD-1
 Checkpoint inhibitors
 Immune-related
 Nivolumab
 Pembrolizumab
 Side-effect
 Tolerability
 Toxicity
K10plus-PPN:1668308851
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68403492   QR-Code
zum Seitenanfang